Atomic bomb prompts research into transplantation as a treatment for radiation marrow injury.

Dr. Georges Mathé performs the first successful allogeneic bone marrow transplant (BMT) in a patient with leukemia, using cells from multiple related donors.

Dr. Mortimer M. Bortin and colleagues establish the International Bone Marrow Transplant Registry (IBMTR), collecting outcomes data on transplant patients; Dr. Bortin serves as first Scientific Director (1972-1991).

Laura Graves becomes the first Fred Hutch patient to receive marrow from an unrelated donor to treat her leukemia.

Dr. Robert Peter Gale serves as the first IBMTR Chair (serving 1980-1997).

Dr. E. Donnall Thomas reports the first attempts at allografting resulting in transient engraftment in the New England Journal of Medicine; Dr. Thomas would later be awarded the Nobel Prize for his work advancing clinical transplantation.

Dr. Robert Good of the University of Minnesota performs the first successful human leukocyte antigen (HLA)-matched sibling (non-twin) transplant for an immunological deficiency disease – clinical transplantation takes off, primarily for non-malignant disorders.

First successful unrelated donor transplant performed at Memorial Sloan Kettering Cancer Center.

Dr. Al Rimm becomes first Statistical Director (serving 1980-1993).

CONTINUED ON NEXT SLIDE

1980-1988
Information begins to move from paper to computers.

IBMTR members visit Park City, Utah, to attend the UCLA Symposia for the first time – marking the beginning of the “annual meetings”.

Dr. Mary Horowitz joins the IBMTR.

The biorepository is established.

US Organ Transplant Amendments Act mandates collecting outcome data for both donors and recipients (Recipient Registry is established).

Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia.

IBMTR receives first major National Institutes of Health (NIH) grant funding.

Dr. Bob Graves, Adm. Elmo Zumwalt, and colleagues establish the National Marrow Donor Program (NMDP) with funds appropriated by the US government.

NMDP facilitates its first unrelated transplant.
Autologous Blood and Marrow Transplant Registry of North America (ABMTR) established at the Medical College of Wisconsin; Dr. James Armitage subsequently became its first Advisory Committee Chair (serving 1994-1998).

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase

T-cell depletion of HLA-identical transplants in leukemia

Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission

Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor

Graft-versus-leukemia reactions after bone marrow transplantation

Dr. Mary Horowitz begins her 30-year tenure as Chief Scientific Director of the IBMTR/CIBMTR

Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program

The IBMTR and ABMTR align their activities under the Medical College of Wisconsin (MCW) Statistical Center

CONTINUED ON NEXT SLIDE
1995-2003
The IBMTR/ABMTR, in conjunction with the American Society for Blood and Marrow Transplantation (ASBMT – now known as ASTCT, American Society for Transplantation and Cellular Therapy) holds the first BMT Tandem Meetings in Keystone, Colorado.

**1995**

Dr. John Goldman begins term as IBMTR Chair (serving 1998-2001)

**1997**

Solid cancers after bone marrow transplantation

**1998**

Long-term survival and late deaths after allogeneic bone marrow transplantation

Dr. Armand Keating begins term as ABMTR Chair (serving 1998-2001)

**1999**

To conduct large, multi-institutional clinical trials, the IBMTR/ABMTR, NMDP, and Emmes become the Data Coordinating Center and help establish the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), which receives a grant

**2001**

Dr. Alexandra Filipovich serves as IBMTR Chair (serving 2001-2002)

**2001**

Dr. Olle Ringdén elected as IBMTR Chair, serving in this role prior to serving on the CIBMTR Transitional Advisory Committee (serving 2003-2006)

**2003**

Dr. Julie Vose serves as ABMTR Chair (serving 2001-2002)
Dr. Richard Champlin elected as ABMTR Chair, serving in this role prior to serving on the CIBMTR Transitional Advisory Committee (serving 2003-2006)

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia

Drs. Claudio Anasetti and Naynesh Kamani begin terms as CIBMTR Transitional Advisory Committee Chairs (previously serving on NMDP committees, serving 2005-2006)

Dr. Sergio Giralt begins term as CIBMTR Advisory Committee Chair (serving 2006-2008)

Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls

The IBMTR/ABMTR at MCW and the NMDP enter a research affiliation to form the CIBMTR, integrating the research activities of the organizations – Drs. Jeff Chell, Dennis Confer, Dan Weisdorf, and Mary Horowitz play key roles in integrating the two research organizations

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome

Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation

The CIBMTR is awarded the contract (PI: Dr. J. Douglas Rizzo) for the Stem Cell Therapeutic Outcomes Database (SCTOD), part of the C.W. Bill Young (pictured above) Cell Transplantation Program
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

Dr. Stella Davies begins term as CIBMTR Advisory Committee Chair (serving 2008-2011)

Adverse events among 2408 unrelated donors of peripheral blood stem cells: Results of a prospective trial from the National Marrow Donor Program

Dr. Thomas Shea begins term as CIBMTR Advisory Committee Chair (serving 2011-2014)

Peripheral-blood stem cells versus bone marrow from unrelated donors

Electronic data reporting begins

2008 BMT Tandem Meetings reach record attendance of 2,500 registrants, with >500 proposals submitted

Alternative donor transplantation after reduced intensity conditioning; results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia

CONTINUED ON NEXT SLIDE 2014-2019
Dr. Paul Martin begins term as CIBMTR Advisory Committee Chair (serving 2014-2017)

The CIBMTR starts Cellular Therapy Task Force to plan for collection of data on non-BMT cell therapies

Dr. Robert Soiffer begins term as CIBMTR Advisory Committee Chair (serving 2017-2020)

Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

NHLBI awards the CIBMTR a grant (PIs: Mary Eapen and Mary Horowitz) to work with the Cure Sickle Cell Initiative to build a research data ecosystem designed to support investigator-initiated research and clinical trials of curative therapies for sickle cell disease

Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

Receiving initial funding from the National Cancer Institute (NCI), the CIBMTR launches the Cellular Therapy Registry; this grant helped establish the Cellular Immunotherapy Data Resource (CIDR), (PI: Marcelo Pasquini) to accelerate research in cellular therapy for cancer

Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation

The Cure Sickle Cell Initiative is launched by the National Heart, Lung, and Blood Institute (NHLBI), to build a community of patients, advocates, researchers, and scientists to accelerate promising therapies to cure sickle cell disease
The BMT CTN (DCC PIs: Mary Horowitz, Steve Devine, Adam Mendizabal) celebrates its 20th anniversary; achievements include launching >50 trials and publishing >120 peer-reviewed papers.

Building a fit for purpose clinical trials infrastructure to accelerate the assessment of novel hematopoietic cell transplantation strategies and cellular immunotherapies.

National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide.

Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome.

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.

CIBMTR, with ASTCT, hosts its 2021 meeting virtually, with >4,600 registrants.

The CIBMTR celebrates the organization’s 50th anniversary.

Thank you for celebrating 50 years of the CIBMTR, we look forward to the next 50 years!